• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Rituximab linked with reduced chronic immune disease following stem cell transplantation

byAndrew Bishara
August 30, 2013
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD AML

1. Rituximab use is linked with a reduction in chronic graft-vs-host disease following peripheral blood stem cell transplantation.

2. Rituximab is also linked with improved survival following transplantation compared to controls.

Evidence Rating Level: 2 (Good)

Study rundown: Following peripheral blood stem cell transplantation, chronic GVHD (graft-vs-host disease) is a major cause of morbidity and reduced quality of life. While treatments involving T-cell depletion have helped prevent this complication, they have not been successful at improving overall survival. As B-cell-dependent processes have been implicated in the occurrence of chronic GVHD, the authors of this study investigated whether B-cell depletion therapy with rituximab can prevent CVHD, and if this treatment is associated with improvements in mortality. They found that their treatment group had significantly reduced rates of steroid-requiring chronic GVHD, though overall rate of chronic disease was only slightly affected. Furthermore, the rates of transplant-related mortality dropped significantly in this group. Based on these results, the study authors recommend that future prospective studies be done to further investigate potential uses of rituximab as prophylactic therapy following blood stem cell transplantation.

These findings are supported by the controlled design of this prospective study. However, it should be noted that the control population came from patients who had refused to participate in treatment, thus introducing potential variation between the control and treatment arms. As the study authors point out, a phase three randomized, controlled trial will be necessary to further investigate their findings before drawing more concrete conclusions.

RELATED REPORTS

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

AAV gene therapy shows durable benefit in hemophilia B

Tumor-infiltrating clonal hematopoiesis is associated with NSCLC recurrence

Click to read the study in Blood

Relevant Reading: The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation

In-depth [prospective cohort study]: The study authors enrolled a total of 65 subjects for treatment in this trial, and concluded data collection with a median follow-up of 48 months. At the conclusion of the trial, 65 contemporaneous control subjects were randomly selected from a database of stem cell transplant patients who had refused treatment with rituximab. All patients had received peripheral blood stem cell transplants, with AML, CLL/SLL/PLL being the most common diagnoses in both groups. In the treatment arm, rituximab was administered at 100 days, then again at 6, 9, and 12 months following transplantation. The primary outcomes measured included clinician-diagnosed chronic GVHD, whether this complication required systemic corticosteroid therapy, and treatment-related mortality at 2 and 4 years following transplantation.

The study authors found that the incidence of chronic GVHD was 48% and 60% (P = 0.1) in the treatment and control arms, respectively. Furthermore, the 2-year cumulative incidence of systemic steroid-requiring chronic GVHD was 31& and 48.5& (P = 0.015), respectively. The 4-year cumulative incidence of relapse did not differ significantly between the two groups, however, treatment-related survival was 71% in the treatment group vs 56% in the control group at 4 years (P = 0.05).

By Monica Parks and Andrew Bishara

More from this author: Ambrisentan found ineffective against idiopathic pulmonary fibrosis, High-dose prophylaxis for hemophilia increases costs with minimal benefit 

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: AMLchronicCLLcomplicationgraft versus hosthematologyimmunologyoncologyrituximabT-celltransplantationtreatment
Previous Post

Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]

Next Post

Certain cancer therapy innovations not associated with decreasing mortality

RelatedReports

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

July 8, 2025
Primary thromboembolism prophylaxis may be effective in advanced cancer
Hematology

AAV gene therapy shows durable benefit in hemophilia B

July 7, 2025
Lessons from real-world implementation of lung cancer screening
Oncology

Tumor-infiltrating clonal hematopoiesis is associated with NSCLC recurrence

July 7, 2025
All Specialties

Minimally invasive surgery is beneficial for epithelial ovarian cancer 

July 4, 2025
Next Post
Certain cancer therapy innovations not associated with decreasing mortality

Certain cancer therapy innovations not associated with decreasing mortality

Smokeless tobacco use in children has not changed

Racial backgrounds key to shaping the face of smoking-related mortality in South Africa

Classics Series, Landmark Trials in Medicine

Clinical decision rule associated with 40% decrease in ALTE-related hospital admissions [Classics Series]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
  • Nerandomilast slows FVC decline in progressive pulmonary fibrosis
  • 2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.